-
IMM September 2018 Corporate Update
ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company today announces a corporate update. Click here to view
-
2018 Annual General Meeting – All Resolutions Passed
ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, held its AGM earlier today and is pleased to announce that all resolutions were duly passed.
-
ImmuPharma announces positive pre-clinical data on its CIDP programme
Positive results of P140 (Lupuzor™ or Forigerimod) published in the Journal of Autoimmunity in a model of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) The T cell modulator P140 significantly reduced the disease in the murine preclinical model Data provides evidence for the expansion of P140 in an autoimmune indication with ‘Orphan Drug Designation’ ImmuPharma PLC (LSE:IMM),…
-
Annual Report and Accounts Posted to Shareholders
Notice of Annual general Meeting on 28 June 2018 @ 10.30 AM Venue: Sky Light City Tower, 50 Basinghall Street, London, EC2 ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company confirms that the Annual Report and Accounts for the year ended 31 December 2017 has been posted to shareholders.…
-
Further Analysis from its Pivotal Phase III Trial of Lupuzor™ in Patients with Systemic Lupus Erythematosus (SLE) Shows Positive Results in the Europe Cohort1
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce further analysis of the results from its pivotal Phase III trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, a potentially life threatening auto-immune disease. This new data follows the top-line trial results published on 17 April…
-
Immupharma PLC confident on Lupuzor’s™ future
ImmuPharma PLC (LON:IMM) CEO Dimitri Dimitriou and Chairman Tim McCarthy discuss with Proactive Investors the top-line results from their phase III trial of the drug Lupuzor™. The data revealed Lupuzor™ was more effective than the placebo (52.5% versus 44.6%) however because the response rate for those taking the non-active medication plus the “standard of care”…
-
Top line results of Lupuzor™ Pivotal Phase III Trial
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces the results of its pivotal Phase III trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus. Key highlights: Lupuzor™ demonstrated a superior response rate over placebo* (52.5% vs 44.6% “responders”**) in the primary analysis on the Full Analysis Set of…
